Genscript Biotech Corporation (G51) — Cash Flow Quality Index
Genscript Biotech Corporation (G51) has a Cash Flow Quality Index of 0.03x as of December 2024. Operating cash flow of €75.65 Million is below net income of €2.96 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore G51 cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Genscript Biotech Corporation Cash Flow Quality Index (2016–2024)
Historical Cash Flow Quality Index for Genscript Biotech Corporation across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check G51 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Genscript Biotech Corporation (2016–2024)
Year-by-year earnings quality comparison for Genscript Biotech Corporation. For live market cap and the full company financial profile, see Genscript Biotech Corporation market capitalisation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | €75.65 Million | €2.96 Billion | ▼ -99.8% |
| 2018 | 14.50x | €307.66 Million | €21.22 Million | ▲ +1672.8% |
| 2017 | 0.82x | €21.37 Million | €26.12 Million | ▼ -35.7% |
| 2016 | 1.27x | €33.27 Million | €26.17 Million | — |